Alkharabsheh O - Search Results

1

An overview of the toxicities of checkpoint inhibitors in older patients with cancer.

Alkharabsheh O, Kannarkatt P, Kannarkatt J, Karapetyan L, Laird-Fick HS, Al-Janadi A. Alkharabsheh O, et al. J Geriatr Oncol. 2018 Sep;9(5):451-458. doi: 10.1016/j.jgo.2018.02.002. Epub 2018 Mar 19. J Geriatr Oncol. 2018. PMID: 29567089 Review.

2

Metformin and Angiogenesis in Cancer - Revisited.

Kannarkatt J, Alkharabsheh O, Tokala H, Dimitrov NV. Kannarkatt J, et al. Among authors: alkharabsheh o. Oncology. 2016;91(4):179-184. doi: 10.1159/000448175. Epub 2016 Aug 3. Oncology. 2016. PMID: 27487294 Review.

3

Small Molecule 20S Proteasome Enhancer Regulates MYC Protein Stability and Exhibits Antitumor Activity in Multiple Myeloma.

Njomen E, Vanecek A, Lansdell TA, Yang YT, Schall PZ, Harris CM, Bernard MP, Isaac D, Alkharabsheh O, Al-Janadi A, Giletto MB, Ellsworth E, Taylor C, Tang T, Lau S, Bailie M, Bernard JJ, Yuzbasiyan-Gurkan V, Tepe JJ. Njomen E, et al. Among authors: alkharabsheh o. Biomedicines. 2022 Apr 19;10(5):938. doi: 10.3390/biomedicines10050938. Biomedicines. 2022. PMID: 35625675 Free PMC article.

4

The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.

Alkharabsheh O, Sidiqi MH, Aljama MA, Gertz MA, Frankel AE. Alkharabsheh O, et al. Acta Haematol. 2020;143(2):118-123. doi: 10.1159/000500976. Epub 2019 Jul 16. Acta Haematol. 2020. PMID: 31311009 Free article. Review.

5

Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises.

Alkharabsheh O, Trisel Z, Badami S, Aljama MA, Sidiqi MH. Alkharabsheh O, et al. Cancers (Basel). 2021 Dec 27;14(1):113. doi: 10.3390/cancers14010113. Cancers (Basel). 2021. PMID: 35008276 Free PMC article. Review.

6

Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies.

Alkharabsheh O, Frankel AE. Alkharabsheh O, et al. Biomedicines. 2019 Jan 5;7(1):6. doi: 10.3390/biomedicines7010006. Biomedicines. 2019. PMID: 30621282 Free PMC article. Review.

7

Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors.

Manne A, Mulekar MS, Escobar DE, Alsayed A, Sharma G, Prodduturvar P, Khushman M, Howard JH, Gilbert R, Alkharabsheh O. Manne A, et al. Among authors: alkharabsheh o. J Clin Med Res. 2021 May;13(5):268-275. doi: 10.14740/jocmr4511. Epub 2021 May 25. J Clin Med Res. 2021. PMID: 34104278 Free PMC article.

8

Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy.

Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, Alkhateeb HB, Patnaik MS, Hogan WJ, Litzow MR, Al-Kali A. Alkharabsheh OA, et al. Ann Hematol. 2019 Feb;98(2):331-337. doi: 10.1007/s00277-018-3509-0. Epub 2018 Oct 18. Ann Hematol. 2019. PMID: 30334068 Clinical Trial.

9

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.

Alkharabsheh O, Alsayed A, Morlote DM, Mehta A. Alkharabsheh O, et al. Curr Oncol. 2021 Feb 8;28(1):837-841. doi: 10.3390/curroncol28010081. Curr Oncol. 2021. PMID: 33567487 Free PMC article.

10

The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS.

Alkharabsheh O, Al-Kali A, Saadeh S, He R, Viswanatha D, Greipp P, Reichard K, Shah M, Gangat N, Patnaik M, Hogan W, Litzow M, Alkhateeb H, Nguyen PL. Alkharabsheh O, et al. Am J Hematol. 2018 Nov;93(11):E355-E357. doi: 10.1002/ajh.25239. Epub 2018 Oct 2. Am J Hematol. 2018. PMID: 30074268 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

21 results

Search Page